Nanomedicine for the diagnosis and treatment of atherosclerosis

An article published in a volume of Nature Reviews Cardiology suggests that the utilization of nanotechnology holds the potential to enhance our comprehension of the underlying causes of atherosclerosis, thus contributing significantly to the advancement of innovative diagnostic techniques and treatment approaches. The predominant pathological mechanisms implicated in atherosclerosis encompass the recruitment of monocytes, accumulation and proliferation of macrophages, impaired efferocytosis, inflammation within plaques, and the buildup of cholesterol. These processes stand out as noteworthy focal points for the development of strategies aimed at regressing and stabilizing atherosclerotic plaques. Given that macrophages play a pivotal role in the progression of atherosclerosis, targeting the pro-atherosclerotic pathways mediated by these cells becomes a crucial pursuit.
Nanotechnology presents distinct advantages due to its ability to markedly enhance the pharmacokinetic characteristics and chemical stability of agents intended for the management of atherosclerosis. The deliberate design of imaging agents based on nanoparticles, capable of selectively homing in on inflammatory macrophages within atherosclerotic plaques, holds promising diagnostic prospects. These agents could offer a non-invasive means to quantitatively assess the burden of atherosclerotic plaques, gauge the effectiveness of medical interventions, and serve as surrogate endpoints for evaluation. For more in-depth information, please refer to the provided link.